Newsroom

We're building precision medicine products for chronic inflammatory disease management and oncology, starting with a blood test to guide treatment decisions in rheumatoid arthritis.

Stay up to date on everything happening at Aqtual.

Press Releases

Aqtual Presents New Data on Development of RA Therapy Selection Test at ACR Convergence 2024

Clinical Trial Progress Supports 2025 Launch of First-of-Its-Kind Blood-Based Test

11/18/2024

Aqtual to Present Data on Innovative Approach to Rheumatoid Arthritis Therapy Selection at CCR East 2024

05/09/2024

Aqtual Announces Appointment of Medical, Translational Research and Data Integrity Executives

04/16/2024

Aqtual to Present Poster at American Association for Cancer Research Annual Meeting 2024

03/27/2024

Aqtual Names Gregg C. Fergus to its Board of Directors

12/19/2023

New Research Demonstrates Aqtual's Platform Identifies Synovial Signatures in Patients with Rheumatoid Arthritis Using a Routine Blood Test

11/15/2023

Aqtual Raises $16 Million in Series A Funds, Initiates PRIMA-102 to Study its Novel Cell-Free DNA Platform in Rheumatoid Arthritis

10/31/2023

Media Coverage

Aqtual Unveils Precision Medicine Platform with Blood-Based Rheumatoid Arthritis Test

GenomeWeb

12/01/2023

Novel Blood Test Can Detect Rheumatoid Arthritis

Medscape

11/20/2023

Diana Abdueva, PhD: Novel Blood-Based Assay Differentiates Seropositive and Seronegative Rheumatoid Arthritis, Healthy Subjects

HCP Live

11/15/2023

Liquid Biopsy Startup Aqtual Raises $16M in Series A Financing

GenomeWeb

10/31/2023

Aqtual raises $16M for liquid biopsy test for rheumatoid arthritis based on cell-free DNA platform

Endpoints

10/31/2023